The Most Important Idea In AI: Recursive Self Improvement

There is a quote often attributed to Einstein: compound interest is the eighth wonder of the world. He who understands it, ...

How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...
Hosted on MSN

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Can this AI stock bounce back in 2026?

It's not looking too good for the biotech.
Insider Monkey

Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...
Seeking Alpha

Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
AOL

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
The Motley Fool

If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...